Current clinical applications of in vivo gene therapy with AAVs

JR Mendell, SA Al-Zaidy, LR Rodino-Klapac… - Molecular Therapy, 2021 - cell.com
Hereditary diseases are caused by mutations in genes, and more than 7,000 rare diseases
affect over 30 million Americans. For more than 30 years, hundreds of researchers have …

Advancements in AAV-mediated gene therapy for Pompe disease

SM Salabarria, J Nair, N Clement… - Journal of …, 2020 - content.iospress.com
Pompe disease (glycogen storage disease type II) is caused by mutations in acid α-
glucosidase (GAA) resulting in lysosomal pathology and impairment of the muscular and …

Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease

J Hordeaux, L Dubreil, C Robveille, J Deniaud… - Acta Neuropathologica …, 2017 - Springer
Pompe disease is a lysosomal storage disorder caused by acid-α-glucosidase (GAA)
deficiency, leading to glycogen storage. The disease manifests as a fatal cardiomyopathy in …

Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease

J Wang, CJ Zhou, A Khodabukus, S Tran… - Communications …, 2021 - nature.com
In Pompe disease, the deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA)
causes skeletal and cardiac muscle weakness, respiratory failure, and premature death …

Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in Pompe disease: preclinical to clinical planning

M Corti, B Cleaver, N Clement, TJ Conlon… - Human Gene …, 2015 - liebertpub.com
A recombinant serotype 9 adeno-associated virus (rAAV9) vector carrying a transgene that
expresses codon-optimized human acid alpha-glucosidase (hGAA, or GAA) driven by a …

[HTML][HTML] Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy

BJ Byrne, DD Fuller, BK Smith, N Clement… - Annals of …, 2019 - ncbi.nlm.nih.gov
Pompe disease is a neuromuscular disease caused by a deficiency of the lysosomal
enzyme acid alpha-glucosidase leading to lysosomal and cytoplasmic glycogen …

Correcting N euromuscular D eficits W ith G ene T herapy in P ompe D isease

AG Todd, JA McElroy, RW Grange, DD Fuller… - Annals of …, 2015 - Wiley Online Library
Objective We have recently reported on the pathology of the neuromuscular junction (NMJ)
in Pompe disease, reflecting disruption of neuronal and muscle homeostasis as a result of …

Copackaged AAV9 vectors promote simultaneous immune tolerance and phenotypic correction of Pompe disease

PA Doerfler, AG Todd, N Clement, DJ Falk… - Human gene …, 2016 - liebertpub.com
Pompe disease is a progressive neuromuscular disorder caused by lysosomal accumulation
of glycogen from a deficiency in acid alpha-glucosidase (GAA). Replacement of the missing …

Motor planning perturbation: muscle activation and reaction time

S Delmas, A Casamento-Moran… - Journal of …, 2018 - journals.physiology.org
Reaction time (RT) is the time interval between the appearance of a stimulus and initiation of
a motor response. Within RT, two processes occur, selection of motor goals and motor …

Electrodiagnostic evaluation of individuals implanted with extracellular matrix for the treatment of volumetric muscle injury: case series

N Han, MA Yabroudi, K Stearns-Reider… - Physical …, 2016 - academic.oup.com
Background Electrodiagnosis can reveal the nerve and muscle changes following surgical
placement of an extracellular matrix (ECM) bioscaffold for treatment of volumetric muscle …